{"id":"rotigotine-transdermal-patch","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Application site reactions (erythema, pruritus)"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Dizziness"},{"rate":"5-10","effect":"Somnolence"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Vomiting"},{"rate":"5-10","effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rotigotine binds to and activates dopamine receptors (D1-D5), with particular affinity for D3 receptors. By providing continuous transdermal dopaminergic stimulation, it compensates for the loss of dopamine-producing neurons characteristic of Parkinson's disease and restores motor control and reduces symptoms of restlessness in RLS.","oneSentence":"Rotigotine is a non-ergot dopamine agonist that stimulates dopamine receptors in the brain to restore dopaminergic neurotransmission.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:19.360Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Restless legs syndrome (RLS)"}]},"trialDetails":[{"nctId":"NCT05886582","phase":"PHASE2","title":"Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2023-09-11","conditions":"Substance-Related Disorders","enrollment":40},{"nctId":"NCT07015346","phase":"NA","title":"Adhesion and Safety of Rotigexole Compared to Neupro®","status":"NOT_YET_RECRUITING","sponsor":"Eva Pharma","startDate":"2025-09-01","conditions":"Idiopathic Parkinson Disease","enrollment":40},{"nctId":"NCT01519882","phase":"PHASE4","title":"Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease","status":"TERMINATED","sponsor":"UCB Pharma SA","startDate":"2012-03","conditions":"Advanced Idiopathic Parkinson's Disease","enrollment":1},{"nctId":"NCT06702124","phase":"PHASE3","title":"A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease","status":"RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2023-12-01","conditions":"Alzheimer Disease","enrollment":348},{"nctId":"NCT04937452","phase":"PHASE2","title":"Dopaminergic Therapy for Frontotemporal Dementia Patients","status":"COMPLETED","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2021-06-03","conditions":"Frontotemporal Dementia, Dementia, Aphasia, Primary Progressive","enrollment":75},{"nctId":"NCT06247410","phase":"PHASE2","title":"Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2021-08-23","conditions":"Parkinson Disease","enrollment":38},{"nctId":"NCT03992196","phase":"PHASE3","title":"A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome","status":"TERMINATED","sponsor":"UCB Biopharma SRL","startDate":"2019-12-03","conditions":"Restless Legs Syndrome","enrollment":10},{"nctId":"NCT03728933","phase":"PHASE3","title":"A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause","status":"TERMINATED","sponsor":"UCB Biopharma SRL","startDate":"2018-12-20","conditions":"Restless Legs Syndrome","enrollment":23},{"nctId":"NCT02138357","phase":"PHASE4","title":"Butrans for Treatment of Restless Legs Syndrome","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-04","conditions":"Restless Legs Syndrome","enrollment":""},{"nctId":"NCT03733561","phase":"PHASE1","title":"A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2018-11-09","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT04183634","phase":"PHASE1","title":"An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.","status":"TERMINATED","sponsor":"Sandoz","startDate":"2019-12-03","conditions":"Parkinson Disease","enrollment":31},{"nctId":"NCT04384666","phase":"PHASE1","title":"A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2020-06-02","conditions":"Parkinson Disease","enrollment":56},{"nctId":"NCT02365870","phase":"PHASE4","title":"Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2016-08","conditions":"Anxiety Disorders, Parkinson Disease","enrollment":4},{"nctId":"NCT03250741","phase":"PHASE2","title":"Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2016-06","conditions":"Alzheimer Disease","enrollment":94},{"nctId":"NCT01782222","phase":"PHASE4","title":"Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2013-02","conditions":"Idiopathic Parkinson's Disease","enrollment":122},{"nctId":"NCT00599339","phase":"","title":"Transdermal Rotigotine User Surveillance Study","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-06","conditions":"Idiopathic Parkinson Disease","enrollment":2195},{"nctId":"NCT01495793","phase":"PHASE2","title":"Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2011-12","conditions":"Restless Legs Syndrome","enrollment":42},{"nctId":"NCT01646255","phase":"PHASE3","title":"Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-07","conditions":"Idiopathic Parkinson's Disease","enrollment":346},{"nctId":"NCT01498120","phase":"PHASE2","title":"Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2011-12","conditions":"Restless Legs Syndrome","enrollment":14},{"nctId":"NCT03098368","phase":"PHASE4","title":"Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2016-09","conditions":"Nocturnal Hypokinesia","enrollment":40},{"nctId":"NCT02227355","phase":"","title":"Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2014-09","conditions":"Idiopathic Parkinson's Disease","enrollment":195},{"nctId":"NCT02727205","phase":"PHASE1","title":"Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch","status":"COMPLETED","sponsor":"Inflamax Research Incorporated","startDate":"2013-08","conditions":"Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch","enrollment":260},{"nctId":"NCT02103465","phase":"PHASE2","title":"Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease","status":"TERMINATED","sponsor":"Azienda Ospedaliera Cardinale G. Panico","startDate":"2013-12","conditions":"Parkinson's Disease","enrollment":80},{"nctId":"NCT01523301","phase":"PHASE4","title":"Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients","status":"COMPLETED","sponsor":"UCB Korea Co., Ltd.","startDate":"2012-04","conditions":"Idiopathic Parkinson's Disease","enrollment":380},{"nctId":"NCT02230904","phase":"PHASE1","title":"A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2014-09","conditions":"Parkinson's Disease","enrollment":57},{"nctId":"NCT01646268","phase":"PHASE3","title":"Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-07","conditions":"IDIOPATHIC PARKINSON'S DISEASE","enrollment":249},{"nctId":"NCT02123979","phase":"PHASE2","title":"Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model","status":"UNKNOWN","sponsor":"East Carolina University","startDate":"2015-11","conditions":"Post-op Pain","enrollment":50},{"nctId":"NCT00474058","phase":"PHASE3","title":"Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-05","conditions":"Parkinson's Disease","enrollment":287},{"nctId":"NCT01744496","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-11","conditions":"Advanced Idiopathic Parkinson's Disease","enrollment":68},{"nctId":"NCT01537042","phase":"PHASE3","title":"A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-04","conditions":"Restless Legs Syndrome, End-Stage Renal Disease","enrollment":30},{"nctId":"NCT00522379","phase":"PHASE3","title":"Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-07","conditions":"Parkinson's Disease","enrollment":514},{"nctId":"NCT00519532","phase":"PHASE3","title":"Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease","status":"TERMINATED","sponsor":"UCB Pharma","startDate":"2007-07","conditions":"Parkinson's Disease","enrollment":84},{"nctId":"NCT00292227","phase":"PHASE1","title":"Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-01","conditions":"Parkinson's Disease","enrollment":130},{"nctId":"NCT00881894","phase":"PHASE1","title":"Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-10","conditions":"Healthy","enrollment":52},{"nctId":"NCT00957944","phase":"PHASE1","title":"Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-07","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT01095484","phase":"","title":"Named Patient Program With Rotigotine Transdermal System","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-11","conditions":"Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine","enrollment":520},{"nctId":"NCT01854216","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2002-12","conditions":"Healthy","enrollment":26},{"nctId":"NCT01761526","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2002-10","conditions":"Healthy","enrollment":50},{"nctId":"NCT00594464","phase":"PHASE4","title":"A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-09","conditions":"Parkinson's Disease","enrollment":14},{"nctId":"NCT00505687","phase":"PHASE3","title":"An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-02","conditions":"Idiopathic Parkinson's Disease","enrollment":186},{"nctId":"NCT00594386","phase":"PHASE3","title":"An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-08","conditions":"Parkinson's Disease","enrollment":258},{"nctId":"NCT00498186","phase":"PHASE2","title":"Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-07","conditions":"Restless Legs Syndrome","enrollment":295},{"nctId":"NCT00593606","phase":"PHASE3","title":"Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-07","conditions":"Parkinson's Disease","enrollment":124},{"nctId":"NCT00243945","phase":"PHASE3","title":"A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-12","conditions":"IDIOPATHIC PARKINSON'S DISEASE","enrollment":58},{"nctId":"NCT00263068","phase":"PHASE3","title":"An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-12","conditions":"Restless Legs Syndrome","enrollment":279},{"nctId":"NCT00242008","phase":"PHASE3","title":"A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-12","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT00243971","phase":"PHASE3","title":"A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-11","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT01569464","phase":"PHASE3","title":"Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-03","conditions":"Restless Legs Syndrome","enrollment":150},{"nctId":"NCT02070796","phase":"PHASE1","title":"Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2014-02","conditions":"Healthy","enrollment":50},{"nctId":"NCT01562743","phase":"PHASE2","title":"A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-08","conditions":"Idiopathic Restless Legs Syndrome","enrollment":185},{"nctId":"NCT01711866","phase":"PHASE4","title":"A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-09","conditions":"Advanced Idiopathic Parkinson's Disease","enrollment":87},{"nctId":"NCT01631812","phase":"PHASE2","title":"A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2006-12","conditions":"Parkinson's Disease","enrollment":130},{"nctId":"NCT01631825","phase":"PHASE3","title":"A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-10","conditions":"Parkinson's Disease","enrollment":321},{"nctId":"NCT01628965","phase":"PHASE2, PHASE3","title":"A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-01","conditions":"Parkinson's Disease","enrollment":143},{"nctId":"NCT01634243","phase":"PHASE2","title":"A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2005-01","conditions":"Parkinson's Disease","enrollment":64},{"nctId":"NCT01628848","phase":"PHASE2","title":"A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2006-08","conditions":"Parkinson's Disease","enrollment":174},{"nctId":"NCT01159691","phase":"","title":"Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch","status":"COMPLETED","sponsor":"UCB Pharma GmbH","startDate":"2010-06","conditions":"Idiopathic Parkinson's Disease","enrollment":76},{"nctId":"NCT01675024","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT01565018","phase":"PHASE1","title":"Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-03","conditions":"Healthy Volunteers","enrollment":55},{"nctId":"NCT01059903","phase":"PHASE1","title":"Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-01","conditions":"Healthy Volunteers","enrollment":50},{"nctId":"NCT01338896","phase":"PHASE1","title":"Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-04","conditions":"Parkinson's Disease","enrollment":56},{"nctId":"NCT00663338","phase":"PHASE2","title":"Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-01","conditions":"Right Hemisphere Stroke, Hemispatial Neglect, Motor Deficit","enrollment":20},{"nctId":"NCT00001931","phase":"PHASE2","title":"Treatment of Parkinson's Disease With a Transdermal Skin Patch","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1999-05","conditions":"Parkinson Disease","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":88,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neupro","Neupro®","ROTIGOTINE"],"phase":"marketed","status":"active","brandName":"Rotigotine transdermal patch","genericName":"Rotigotine transdermal patch","companyName":"UCB BIOSCIENCES GmbH","companyId":"ucb-biosciences-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rotigotine is a non-ergot dopamine agonist that stimulates dopamine receptors in the brain to restore dopaminergic neurotransmission. Used for Parkinson's disease, Restless legs syndrome (RLS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}